Regeneron Pharmaceuticals, Inc. and Sanofi announced positive pivotal results from a second Phase 3 trial, PRIME, evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo...
Regulated information – Inside information – UCB announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc.,...
ValGenesis, Inc., a market leader in enterprise Validation Lifecycle Management Systems (VLMS), announced that a leading Italian pharmaceutical company selected ValGenesis VLMS – the...
The human gut is inhabited by a plethora of micro-organisms, collectively called the "microbiota," which are important for normal physiological processes. "Dysbiosis" or an...
Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from...
